

# MEDICAMENT

## MEDICAL MARIJUANA RESEARCH NEWSLETTER



SPRING 2024

### WELCOME TO MEDICAMENT,

the Consortium for Medical Marijuana Clinical Outcomes Research's quarterly newsletter.

The Consortium, founded by the State of Florida, conducts, disseminates, and supports research on the use and effects of medical marijuana on patient outcomes.

*In the Spring 2024 issue of  
MEDICAMENT:*

- Annual Report 2023-2024
- Cannabis Clinical Outcomes Research Conference (CCORC)
- Announcing CCORC 2024 Keynote Speakers
- Outreach Announcements
- Research Grants Program
- Journal Corner
- Medical Marijuana and Me (M<sup>3</sup>)
- Get Involved in Research



Consortium for  
Medical Marijuana  
Clinical Outcomes Research

To learn more about the Consortium and our programs, visit us at [mmjoutcomes.org](https://mmjoutcomes.org).

### ANNUAL REPORT 2023-2024



#### Consortium Releases Annual Report

In February, the Consortium released its fifth annual report detailing its accomplishments during 2023-2024 and presenting plans for future initiatives within each of the Consortium's five pillars: the Grants Program, MEMORY, Clinical Core, Evidence Core, and Outreach.

[Read the Annual Report here >](#)

### CCORC 2024: REGISTER TODAY

Early Bird Pricing Ends April 15

Registration is now open for the fourth annual Cannabis Clinical Outcomes Research Conference (CCORC).



CANNABIS CLINICAL OUTCOMES  
RESEARCH CONFERENCE 2024

MAY 30-31, 2024 | ORLANDO, FL

*Learn, Share, and Advance Medical Marijuana Research*

MORE INFORMATION AT [CCORC.MMJOUTCOMES.ORG](https://CCORC.MMJOUTCOMES.ORG)



REGISTER HERE

# ANNOUNCING CCORC 2024 KEYNOTE SPEAKERS

Three Top Experts in Cannabis Research Selected to Present at Annual Conference



## **Ryan Vandrey, PhD**

**Johns Hopkins University | Behavioral Pharmacology Research Unit**

**Title of Presentation:** *Using Laboratory Science to Inform Clinical Decision Making and Patient Safety in Medicinal Cannabis*

Dr. Ryan Vandrey is a Professor at the Johns Hopkins University Behavioral Pharmacology Research Unit. Dr. Vandrey's research focuses primarily on the impact of route of administration, dose, and chemical composition of cannabis products on resultant drug effects and pharmacokinetics. Also, the risks and benefits of medicinal cannabis use, cannabis drug interactions, the effects of cannabis use on sleep, cannabis withdrawal and the treatment of Cannabis Use Disorder, product testing, and developing measures of cannabis use behavior.



## **Matthew Hill, PhD**

**University of Calgary | Hotchkiss Brain Institute**

**Title of Presentation:** *Cannabis, Endocannabinoids and PTSD*

Dr. Matthew Hill is a Professor in the Departments of Cell Biology and Anatomy and Psychiatry at the Hotchkiss Brain Institute. Dr. Hill's research has demonstrated that the brain produces "endocannabinoids" (the brain's own version of molecules like THC from cannabis) in response to stress to help us recover appropriately, and has found that chronic stress compromises how the "endocannabinoid" system functions, identifying this system as target for both the pathophysiology and treatment of stress related mood and anxiety disorders.



## **Margaret Haney, PhD**

**Columbia University | Irving Medical Center**

**Title of Presentation:** *Cannabis Use Disorder*

Dr. Margaret Haney is a Professor of Neurobiology at the Columbia University Irving Medical Center. As the Director of the Cannabis Research Laboratory and Co-Director of the Substance Use Research Center, Dr. Haney is internationally recognized for her expertise in human laboratory studies of cannabis and cannabinoids. Her interest is both in conducting placebo controlled studies testing the efficacy of treatment medications for Cannabis Use Disorder and in testing the potential therapeutic effects of cannabis and cannabinoids.

## OUTREACH ANNOUNCEMENTS

### Dr. Amie Goodin, Lead of Evidence Core at the Consortium, Weighs in on Marijuana and Mental Health

The Consortium's Dr. Amie Goodin was recently interviewed with xoNecole to provide insight into the relationship between marijuana and mental health. The article, entitled, "**Is Weed Having an Effect on Your Mental Health? Here's How to Cut the Habit**" delves into the potential impacts of cannabis consumption on mental well-being.

The article aims to address whether individuals develop anxiety and depression due to cannabis use or if they use cannabis products as a coping mechanism for existing mental health issues. Dr. Goodin discusses the observed trend of increased anxiety and depression among teenagers and young adults who use cannabis frequently. She explains that frequent and early cannabis use may lead to worse anxiety and depression outcomes.

Dr. Goodin highlights signs to look out for to assess whether marijuana usage should be reduced or stopped, such as changes in social interactions, work or school performance, and sleep patterns and provides tips for quitting cannabis use.

[READ THE FULL ARTICLE](#)

## RESEARCH GRANTS PROGRAM

### 2024 Grants Program: Letters of Intent and Proposals


The Consortium for Medical Marijuana Clinical Outcomes Research received 32 letters of interest (LOI) from faculty from seven of its member institutions, in response to its sixth Request for Proposals (RFP) for the 2024 Research Grants Program.

After review and Board approval, 28 LOIs were found to be responsive to the research priorities of the Consortium. The Principal Investigators of these 28 LOIs were invited for full proposal submission, 27 of whom confirmed full proposal submission.

The deadline for invited full proposal submission is April 3rd, 2024, at 11:59 PM EST via email to [mmj.outcomes@cop.ufl.edu](mailto:mmj.outcomes@cop.ufl.edu). The Consortium will announce final decisions regarding funding by July 1st, 2024.

# JOURNAL CORNER

## Updates from Karger, Publisher of the Consortium's Official Journal



*Medical Cannabis and Cannabinoids* is the official journal of the Consortium, offering an international forum to investigate cannabis safety and effectiveness when used for medical purposes. This series in the newsletter, Journal Corner, provides updates, information and resources from the journal publisher, Karger.

### The Latest Published Study from Consortium Members

[Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects](#) (Qingchen Zhang, Philip W. Melchert, John S. Markowitz) *Med Cannabis Cannabinoids* 2024;7:1-9; DOI 10.1159/000535726)

### Research Integrity and Publication Ethics at Karger

Both the scholarly and general press have recently reported on concerns about research integrity and publication ethics, including the problems of paper mills, manipulated images, and plagiarism. Karger, the publisher of *Medical Cannabis and Cannabinoids*, has taken several steps to safeguard the scholarly record and ensure a fair peer-review process for the articles going into its publications. With the Research Integrity and Publication Ethics team, headed by Grainne McNamara, Karger uses several tools including AI-based applications to identify concerns and issues, such as identifying manipulated or duplicate images. Karger contributed to research led by the Committee on Publication Ethics (COPE), of which they are a member, on the phenomenon of paper mills and is a member of the COPE working group on this problem. Karger is also a part of the [STM Integrity Hub](#) and the [United2Act](#) initiative, a cross-publisher interest group formed to tackle the issues of paper mills and post-publication corrections.

### Want to learn more? Visit these free resources:

- [Paper mills research | COPE: Committee on Publication Ethics](#)
- [Correcting the scholarly record, and dispelling myths around corrections.\(youtube.com\)](#)

### Medical Cannabis and Cannabinoids at a Glance

- Official journal of the Consortium for Medical Marijuana Clinical Outcomes Research
- Consortium members are eligible for an APC discount of 50% on accepted articles
- Open Access
- Indexed in PMC, DOAJ, Scopus
- CiteScore: 6.3

For more information or questions about *Medical Cannabis and Cannabinoids*, contact: Alan Tootle, Publication Manager, [a.tootle@karger.com](mailto:a.tootle@karger.com).



# MEDICAL MARIJUANA & ME UPDATE

## M<sup>3</sup> Longitudinal Study Data Access Coming Soon

Data from the Medical Marijuana and Me (M<sup>3</sup>) longitudinal study will soon be available for interested researchers. The data summarize information on utilization patterns and health outcomes from 602 new MMJ users addressing questions within the following suggested domain and others:

- Comorbidities
- Concurrent Medication Use
- Concurrent Substance Use
- Demographic Characteristics of the Study Participants
- MMJ Products and Use Patterns
- MMJ-Related Side Effects
- Perceived Effects on Physical and Mental Health
- Reasons for Using MMJ

The Data Access Request Application is now open for submissions. Data from the cross-sectional study are available. More information is available at [mmjoutcomes.org/m3study](https://mmjoutcomes.org/m3study). If you have questions or would like to speak to a study team member, you may call/text [\(352\) 658-3735](tel:3526583735) or email [m3cohort@phhp.ufl.edu](mailto:m3cohort@phhp.ufl.edu).

## GET INVOLVED IN RESEARCH

CARMMA: Changing the way we collaborate across the state of Florida

The [Connect and Advance Research for Medical Marijuana Analysis \(CARMMA\) Database](#) is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research. Anyone interested in engaging in medical marijuana research is invited to register in CARMMA to find collaborators.

Have news or feedback to share?  
Let us know!

Share your Consortium-related research and news through our [submission form](#).

Share your comments on our newsletter through our [feedback form](#).

Don't want to miss any  
MEDICAMENT issues?

Share your contact information through our [newsletter sign-up form](#).

[Read previous MEDICAMENT issues on our website.](#)



Consortium for  
Medical Marijuana  
Clinical Outcomes Research